1. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Issue 3 (September 2015) Authors: Kossai, M.; Duchemann, B.; Boutros, C.; Caramella, C.; Hollebecque, A.; Angevin, E.; Gazzah, A.; Bahleda, R.; Ileana, E.; Massard, C.; Vielh, P.; Soria, J.C.; Besse, B. Journal: Lung cancer Issue: Volume 89:Issue 3(2015:Sep.) Page Start: 306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients. (February 2019) Authors: Charrier, M.; Mezquita, L.; Lueza, B.; Dupraz, L.; Planchard, D.; Remon, J.; Caramella, C.; Cassard, L.; Boselli, L.; Reiners, K.S.; Pogge von Strandmann, E.; Rusakiewicz, S.; Ferrara, R.; Duchemann, B.; Naigeon, M.; Pignon, J.P.; Besse, B.; Chaput, N. Journal: European journal of cancer Issue: Volume 108(2019) Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Nivolumab-refractory patients with advanced non-small-cell lung cancer. (April 2019) Authors: Costantini, A.; Fallet, V.; Corny, J.; Friard, S.; Chouaid, C.; Duchemann, B.; Giroux-Leprieur, E.; Taillade, L.; Doucet, L.; Brosseau, S.; Wislez, M.; Tredaniel, J.; Cadranel, J. Journal: Lung cancer Issue: Volume 130(2019) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗